cjc1295 without dac ipamorelin CJC-1295 (5mg) / (5mg) CJC1295 Without DAC | C152H252N44O42

Developed by Novo Nordisk in the late 1990s, ipamorelin stimulates growth hormone (GH) release from somatotroph cells in the anterior pituitary gland through direct receptor activation, triggering the Gq/11-phospholipase C signalling cascade that leads to calcium-mediated exocytosis of GH-containing secretory granules

WO 2015/161276, the disclosure of which is hereby incorporated by reference and described herein below

Results may vary depending on individual health status and treatment frequency

At Perfect B in Doral, FL, CJC-1295/Ipamorelin is part of a clinical evaluation that begins with baseline labs, includes provider review of hormonal status, and is adjusted based on your response data throughout the protocol